Literature DB >> 24944463

Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.

Evangelista Sagnelli1, Caterina Sagnelli1, Mariantonietta Pisaturo1, Nicola Coppola1.   

Abstract

The hepatitis C virus (HCV) causes an acute infection that is frequently asymptomatic, but a spontaneous eradication of HCV infection occurs only in one-third of patients. The remaining two-thirds develop a chronic infection that, in most cases, shows an indolent course and a slow progression to the more advanced stages of the illness. Nearly a quarter of cases with chronic hepatitis C (CHC) develop liver cirrhosis with or without hepatocellular carcinoma. The indolent course of the illness may be troubled by the occurrence of a hepatic flare, i.e., a spontaneous acute exacerbation of CHC due to changes in the immune response, immunosuppression and subsequent restoration, and is characterized by an increase in serum aminotransferase values, a frequent deterioration in liver fibrosis and necroinflammation but also a high frequency of sustained viral response to pegylated interferon plus ribavirin treatment. A substantial increase in serum aminotransferase values during the clinical course of CHC may also be a consequence of a superinfection by other hepatotropic viruses, namely hepatitis B virus (HBV), HBV plus hepatitis D virus, hepatitis E virus, cytomegalovirus, particularly in geographical areas with high endemicity levels. The etiology of a hepatic flare in patients with CHC should always be defined to optimize follow-up procedures and clinical and therapeutic decisions.

Entities:  

Keywords:  Chronic hepatitis C virus infection; Hepatic flares; Hepatic flares in immunocompromised patients; Hepatitis A virus superinfection; Immunocompromised patients

Mesh:

Substances:

Year:  2014        PMID: 24944463      PMCID: PMC4051912          DOI: 10.3748/wjg.v20.i22.6707

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  105 in total

1.  Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Salvatore Guastafierro; Gilda Tonziello; Antonello Sica; Valentina Iodice; Caterina Sagnelli; Maria Giovanna Ferrara; Evangelista Sagnelli
Journal:  Dig Liver Dis       Date:  2011-08-31       Impact factor: 4.088

2.  Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.

Authors:  Parag Mahale; Dimitrios P Kontoyiannis; Roy F Chemaly; Ying Jiang; Jessica P Hwang; Marta Davila; Harrys A Torres
Journal:  J Hepatol       Date:  2012-08-04       Impact factor: 25.083

3.  Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course.

Authors:  Evangelista Sagnelli; Nicola Coppola; Cecilia Marrocco; Mirella Onofrio; Caterina Sagnelli; Giancarlo Coviello; Carlo Scolastico; Pietro Filippini
Journal:  J Clin Virol       Date:  2005-11-28       Impact factor: 3.168

4.  Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.

Authors:  Daisuke Ennishi; Yoshinobu Maeda; Nozomi Niitsu; Minoru Kojima; Koji Izutsu; Jun Takizawa; Shigeru Kusumoto; Masataka Okamoto; Masahiro Yokoyama; Yasushi Takamatsu; Kazutaka Sunami; Akira Miyata; Kayoko Murayama; Akira Sakai; Morio Matsumoto; Katsuji Shinagawa; Akinobu Takaki; Keitaro Matsuo; Tomohiro Kinoshita; Mitsune Tanimoto
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

5.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

Review 6.  Sofosbuvir for the treatment of hepatitis C virus.

Authors:  Tarik Asselah
Journal:  Expert Opin Pharmacother       Date:  2013-11-30       Impact factor: 3.889

7.  Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier.

Authors:  Daniele Accapezzato; Francesca Fravolini; Marco Antonio Casciaro; Marino Paroli
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 2.566

8.  Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes.

Authors:  Giuliana Fortunato; Giuseppe Calcagno; Vincenzo Bresciamorra; Elena Salvatore; Alessandro Filla; Silvana Capone; Rosario Liguori; Salvatore Borelli; Ivan Gentile; Francesco Borrelli; Guglielmo Borgia; Lucia Sacchetti
Journal:  J Interferon Cytokine Res       Date:  2008-03       Impact factor: 2.607

9.  Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C.

Authors:  L García-Buey; C García-Monzón; S Rodriguez; M J Borque; A García-Sánchez; R Iglesias; M DeCastro; F G Mateos; J L Vicario; A Balas
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

Review 10.  Immunological determinants of the outcomes from primary hepatitis C infection.

Authors:  J Post; S Ratnarajah; A R Lloyd
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

View more
  7 in total

Review 1.  Hepatitis C virus: A time for decisions. Who should be treated and when?

Authors:  Bashar M Attar; David H Van Thiel
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Chronic hepatitis E: A brief review.

Authors:  Arvind R Murali; Vikram Kotwal; Saurabh Chawla
Journal:  World J Hepatol       Date:  2015-09-08

Review 3.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 4.  Occult HBV infection in the oncohematological setting.

Authors:  C Sagnelli; M Macera; M Pisaturo; R Zampino; M Coppola; E Sagnelli
Journal:  Infection       Date:  2016-04-13       Impact factor: 3.553

5.  Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection.

Authors:  Shuhui Liu; Kaitao Zhao; Xi Su; Xiaoxiao Gao; Yongxuan Yao; Ranran Kong; Yun Wang; Chunchen Wu; Mengji Lu; Xinwen Chen; Rongjuan Pei
Journal:  Virol Sin       Date:  2022-05-03       Impact factor: 6.947

Review 6.  Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients.

Authors:  Armando Calogero; Evangelista Sagnelli; Massimiliano Creta; Silvia Angeletti; Gaia Peluso; Paola Incollingo; Maria Candida; Gianluca Minieri; Nicola Carlomagno; Concetta Anna Dodaro; Massimo Ciccozzi; Caterina Sagnelli
Journal:  Biomed Res Int       Date:  2019-04-07       Impact factor: 3.411

Review 7.  Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Hiroshi Takahashi; Taku Mizutani; Naoki Matsumoto; Kazushige Nirei; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.